SRC and neoplasm: EPO, acting through the canonical EPO-R or through ephrin-type B receptor 4 (EphB4), an alternative EPO-R, may account for the increased tumor growth and progression through downstream activation of the Src-STAT3 pathway seen in cancer patients treated with ESAs [37].